The U.S. Food and Drug Administration (FDA) has issued a complete response letter stating that it will not approve the combination of Keytruda (pembrolizumab) plus Lenvima (lenvatinib) as a first-line treatment for people with advanced unresectable hepatocellular carcinoma (HCC). According to a press release, the decision was made on the basis that there isn’t evidence this treatment combination is meaningfully more effective than other approved treatments. Keytruda, developed by Merck (known as MSD outside the U.S. and Canada), is…
You must be logged in to read/download the full post.
The post FDA Rejects Keytruda-Lenvima Combo as First-line Treatment for Liver Cancer appeared first on BioNewsFeeds.